Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. (Q33927755)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

metastatic renal cell carcinoma

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Frede Donskov

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

11

Toni K Choueiri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Daniel Y C Heng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Wanling Xie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Ulka Vaishampayan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Min-Han Tan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Jennifer Knox

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Lori Wood

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Christian Kollmannsberger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Brian I Rini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

18 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

2637-2642

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

3 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Detecting an overall survival benefit that is derived from progression-free survival

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Progression-free survival is a surrogate for survival in advanced colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856357

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.25750

A statistical model for the dependence between progression-free survival and overall survival

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21656741

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CNCR.25750

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21656741%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

PubMed publication ID

21656741

1 reference